On June 11, Ali Health fell 3.16% in regular trading, trading at HK$3.38 per share, with trading volume of HK$181 million, extending a sustained post-earnings downtrend.

The decline is driven by a combination of selling pressure following the company's earnings release on May 14 and the ongoing impact of new regulatory requirements for online prescription drug sales. The National Medical Products Administration issued the Compliance Guidelines for Online Prescription Drug Retail in late May, explicitly banning the use of artificial intelligence to replace licensed pharmacists in prescription review, prohibiting promotional activities such as buy-one-get-one offers, bundled sales, and livestream-induced medication purchases. These rules are expected to materially increase compliance costs for pharmaceutical e-commerce platforms and pressure near-term profitability.

The broader Internet and Direct Marketing Retail sector traded lower in tandem, with BABA-W down 5.29%, JD-SW down 3.21%, JD Health down 1.79%, PA Good Doctor down 1.60%, and Meituan-W down 1.27%, reinforcing sector-wide selling momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)